Intellia Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

NTLA Stock

USD 12.05 0.05 0.41%

Intellia Therapeutics financial indicator trend analysis is infinitely more than just investigating Intellia Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intellia Therapeutics is a good investment. Please check the relationship between Intellia Therapeutics Free Cash Flow Yield and its Ev To Free Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intellia Therapeutics Free Cash Flow Yield account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Intellia Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is -0.54. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Intellia Therapeutics, assuming nothing else is changed. The correlation between historical values of Intellia Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Intellia Therapeutics are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Free Cash Flow Yield i.e., Intellia Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.54

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Intellia Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.37, whereas Issuance Of Capital Stock is forecasted to decline to about 410.5 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	300.9M	510.3M	551.6M	579.1M
Cost Of Revenue	6.9M	7.6M	9.0M	8.5M

Total Operating Expenses Cost Of Revenue

Intellia Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue
Total Assets		0.92	1.0	1.0	0.78	0.9	0.9	-0.5	-0.82	0.79	0.71	0.88	0.89	0.77	0.99	-0.63	0.94	0.99	0.78	0.88	1.0	0.89	0.98	-0.63	0.75	0.84
Other Current Liab	0.92		0.9	0.92	0.62	0.97	1.0	-0.45	-0.95	0.66	0.68	0.85	0.94	0.91	0.9	-0.55	0.86	0.9	0.87	0.98	0.9	0.99	0.92	-0.55	0.71	0.71
Total Current Liabilities	1.0	0.9		0.99	0.8	0.9	0.89	-0.45	-0.81	0.83	0.66	0.9	0.9	0.74	0.99	-0.66	0.95	0.98	0.79	0.88	0.99	0.88	0.97	-0.66	0.76	0.87
Total Stockholder Equity	1.0	0.92	0.99		0.76	0.9	0.9	-0.49	-0.83	0.78	0.7	0.88	0.89	0.76	0.99	-0.62	0.94	0.98	0.78	0.88	0.99	0.89	0.98	-0.62	0.75	0.84
Other Liab	0.78	0.62	0.8	0.76		0.7	0.62	-0.62	-0.57	0.86	0.7	0.66	0.66	0.64	0.8	-0.78	0.8	0.84	0.61	0.65	0.82	0.61	0.78	-0.78	0.64	0.79
Net Tangible Assets	0.9	0.97	0.9	0.9	0.7		0.99	-0.38	-0.97	0.72	0.61	0.89	0.97	0.92	0.88	-0.58	0.87	0.89	0.95	1.0	0.9	0.99	0.89	-0.58	0.7	0.73
Property Plant And Equipment Net	0.9	1.0	0.89	0.9	0.62	0.99		-0.4	-0.97	0.67	0.64	0.86	0.95	0.91	0.88	-0.55	0.85	0.88	0.91	0.99	0.89	1.0	0.9	-0.55	0.71	0.69
Net Debt	-0.5	-0.45	-0.45	-0.49	-0.62	-0.38	-0.4		0.31	-0.29	-0.96	-0.21	-0.29	-0.55	-0.53	0.57	-0.46	-0.57	-0.15	-0.37	-0.52	-0.38	-0.58	0.57	-0.4	-0.41
Retained Earnings	-0.82	-0.95	-0.81	-0.83	-0.57	-0.97	-0.97	0.31		-0.62	-0.55	-0.8	-0.93	-0.94	-0.79	0.51	-0.81	-0.81	-0.94	-0.99	-0.81	-0.98	-0.83	0.51	-0.68	-0.56
Accounts Payable	0.79	0.66	0.83	0.78	0.86	0.72	0.67	-0.29	-0.62		0.45	0.72	0.7	0.54	0.8	-0.71	0.84	0.83	0.69	0.68	0.83	0.65	0.78	-0.71	0.67	0.74
Cash	0.71	0.68	0.66	0.7	0.7	0.61	0.64	-0.96	-0.55	0.45		0.44	0.53	0.72	0.72	-0.63	0.65	0.76	0.39	0.61	0.72	0.62	0.78	-0.63	0.54	0.55
Non Current Assets Total	0.88	0.85	0.9	0.88	0.66	0.89	0.86	-0.21	-0.8	0.72	0.44		0.96	0.66	0.88	-0.47	0.78	0.85	0.88	0.86	0.88	0.87	0.8	-0.47	0.58	0.87
Non Currrent Assets Other	0.89	0.94	0.9	0.89	0.66	0.97	0.95	-0.29	-0.93	0.7	0.53	0.96		0.83	0.88	-0.5	0.81	0.87	0.95	0.96	0.89	0.96	0.85	-0.5	0.6	0.78
Other Assets	0.77	0.91	0.74	0.76	0.64	0.92	0.91	-0.55	-0.94	0.54	0.72	0.66	0.83		0.74	-0.61	0.77	0.78	0.83	0.93	0.77	0.91	0.81	-0.61	0.66	0.52
Cash And Short Term Investments	0.99	0.9	0.99	0.99	0.8	0.88	0.88	-0.53	-0.79	0.8	0.72	0.88	0.88	0.74		-0.65	0.93	0.98	0.74	0.86	0.99	0.87	0.98	-0.65	0.74	0.88
Common Stock Total Equity	-0.63	-0.55	-0.66	-0.62	-0.78	-0.58	-0.55	0.57	0.51	-0.71	-0.63	-0.47	-0.5	-0.61	-0.65		-0.8	-0.65	-0.48	-0.57	-0.66	-0.52	-0.67	1.0	-0.76	-0.6
Common Stock Shares Outstanding	0.94	0.86	0.95	0.94	0.8	0.87	0.85	-0.46	-0.81	0.84	0.65	0.78	0.81	0.77	0.93	-0.8		0.92	0.77	0.86	0.94	0.84	0.95	-0.8	0.89	0.76
Non Current Liabilities Total	0.99	0.9	0.98	0.98	0.84	0.89	0.88	-0.57	-0.81	0.83	0.76	0.85	0.87	0.78	0.98	-0.65	0.92		0.76	0.87	1.0	0.87	0.98	-0.65	0.73	0.83
Other Current Assets	0.78	0.87	0.79	0.78	0.61	0.95	0.91	-0.15	-0.94	0.69	0.39	0.88	0.95	0.83	0.74	-0.48	0.77	0.76		0.94	0.78	0.92	0.74	-0.48	0.59	0.63
Other Stockholder Equity	0.88	0.98	0.88	0.88	0.65	1.0	0.99	-0.37	-0.99	0.68	0.61	0.86	0.96	0.93	0.86	-0.57	0.86	0.87	0.94		0.88	0.99	0.88	-0.57	0.7	0.68
Total Liab	1.0	0.9	0.99	0.99	0.82	0.9	0.89	-0.52	-0.81	0.83	0.72	0.88	0.89	0.77	0.99	-0.66	0.94	1.0	0.78	0.88		0.88	0.98	-0.66	0.75	0.85
Property Plant And Equipment Gross	0.89	0.99	0.88	0.89	0.61	0.99	1.0	-0.38	-0.98	0.65	0.62	0.87	0.96	0.91	0.87	-0.52	0.84	0.87	0.92	0.99	0.88		0.89	-0.52	0.68	0.68
Total Current Assets	0.98	0.92	0.97	0.98	0.78	0.89	0.9	-0.58	-0.83	0.78	0.78	0.8	0.85	0.81	0.98	-0.67	0.95	0.98	0.74	0.88	0.98	0.89		-0.67	0.78	0.78
Common Stock	-0.63	-0.55	-0.66	-0.62	-0.78	-0.58	-0.55	0.57	0.51	-0.71	-0.63	-0.47	-0.5	-0.61	-0.65	1.0	-0.8	-0.65	-0.48	-0.57	-0.66	-0.52	-0.67		-0.76	-0.6
Property Plant Equipment	0.75	0.71	0.76	0.75	0.64	0.7	0.71	-0.4	-0.68	0.67	0.54	0.58	0.6	0.66	0.74	-0.76	0.89	0.73	0.59	0.7	0.75	0.68	0.78	-0.76		0.57
Current Deferred Revenue	0.84	0.71	0.87	0.84	0.79	0.73	0.69	-0.41	-0.56	0.74	0.55	0.87	0.78	0.52	0.88	-0.6	0.76	0.83	0.63	0.68	0.85	0.68	0.78	-0.6	0.57

Click cells to compare fundamentals

Intellia Therapeutics Account Relationship Matchups

Intellia Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	334.3M	676.3M	1.3B	1.5B	1.3B	686.6M
Other Current Liab	13.3M	19.9M	34.2M	60.9M	48.4M	50.8M
Total Current Liabilities	35.6M	64.3M	125.8M	126.6M	115.2M	64.2M
Total Stockholder Equity	269.9M	527.1M	1.0B	1.2B	1.1B	548.5M
Other Liab	16.1M	51.4M	63.5M	44.0M	50.6M	38.1M
Net Tangible Assets	269.9M	612.1M	1.2B	1.4B	1.6B	1.7B
Property Plant And Equipment Net	37.1M	55.1M	100.1M	161.0M	148.1M	155.5M
Net Debt	(38.9M)	(120.7M)	(49.4M)	(392.8M)	(111.4M)	(117.0M)
Retained Earnings	(300.9M)	(435.1M)	(703.0M)	(1.2B)	(1.7B)	(1.6B)
Accounts Payable	3.9M	10.5M	9.7M	5.2M	7.5M	5.3M
Cash	57.2M	160.0M	123.4M	523.5M	226.7M	203.4M
Non Current Assets Total	44.8M	79.0M	525.2M	303.3M	302.6M	317.8M
Non Currrent Assets Other	2.9M	22.0M	87.7M	73.0M	83.9M	88.1M
Other Assets	2.9M	4.7M	4.8M	15.7M	18.1M	19.0M
Cash And Short Term Investments	279.7M	597.4M	1.1B	1.3B	912.2M	566.6M
Common Stock Shares Outstanding	47.2M	56.0M	70.9M	77.0M	88.8M	50.5M
Liabilities And Stockholders Equity	334.3M	676.3M	1.3B	1.5B	1.3B	686.6M
Non Current Liabilities Total	28.8M	85.0M	128.4M	158.0M	135.6M	73.9M
Other Current Assets	5.1M	14.3M	37.2M	20.4M	49.7M	52.1M
Other Stockholder Equity	570.5M	962.2M	1.7B	2.4B	2.7B	2.8B
Total Liab	64.4M	149.3M	254.2M	284.5M	250.8M	138.1M
Property Plant And Equipment Gross	37.1M	55.1M	126.2M	194.2M	188.0M	197.4M
Total Current Assets	289.5M	597.4M	769.3M	1.2B	998.3M	541.2M
Accumulated Other Comprehensive Income	261K	1K	(2.6M)	(7.5M)	(2.3M)	(2.4M)
Property Plant Equipment	37.1M	15.9M	21.0M	27.9M	32.1M	18.1M
Current Deferred Revenue	12.7M	22.5M	63.8M	43.8M	22.1M	29.3M
Net Receivables	4.6M	2.1M	2.0M	3.8M	36.5M	38.3M
Capital Surpluse	570.5M	962.2M	1.7B	2.4B	2.8B	2.9B
Retained Earnings Total Equity	(300.9M)	(435.1M)	(703.0M)	(1.2B)	(1.1B)	(1.0B)
Short Term Investments	222.5M	437.4M	625.3M	669.1M	685.5M	398.1M
Net Invested Capital	269.9M	527.1M	1.0B	1.2B	1.1B	738.8M
Net Working Capital	253.8M	552.3M	643.5M	1.1B	883.1M	633.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:

How To Invest In Intellia

Details

Is Intellia Stock a good investment?

Details

What is Intellia Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.45)

Revenue Per Share

0.449

Quarterly Revenue Growth

(0.24)

Return On Assets

(0.28)

Return On Equity

(0.52)

The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Intellia Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Ev To Free Cash Flow

Intellia Therapeutics fundamental ratios Correlations

Intellia Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Intellia Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Other Current Liab
Other Stockholder Equity	+ 1.0	Net Tangible Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Other Stockholder Equity	- 0.99	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Retained Earnings	- 0.97	Net Tangible Assets
Cash	- 0.96	Net Debt
Retained Earnings	- 0.95	Other Current Liab